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Vestibular Migraine (VM) and Meniere’s Disease (MD) are episodic vestibular syndromes
defined by a set of associated symptoms such as tinnitus, hearing loss or migraine
features during the attacks. Both conditions may show symptom overlap and there is
no biological marker to distinguish them. Two subgroups of MD patients have been
reported, according to their IL-1β profile. Therefore, considering the clinical similarity
between VM and MD, we aimed to investigate the cytokine profile of MD and VM
as a means to distinguish these patients. We have also carried out gene expression
microarrays and measured the levels of 14 cytokines and 11 chemokines in 129 MD
patients, 82 VM patients, and 66 healthy controls. Gene expression profile in peripheral
blood mononuclear cells (PBMC) showed significant differences in MD patients with high
and low basal levels of IL- 1β and VM patients. MD patients with high basal levels of IL- 1β
(MDH) had overall higher levels of cytokines/chemokines when compared to the other
subsets. CCL4 levels were significantly different between MDH, MD with low basal levels
of IL- 1β (MDL), VM and controls. Logistic regression identified IL- 1β, CCL3, CCL22, and
CXCL1 levels as capable of differentiating VM patients from MD patients (area under the
curve = 0.995), suggesting a high diagnostic value in patients with symptoms overlap.
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INTRODUCTION
Meniere’s Disease (MD) is a syndrome characterized by attacks of recurrent vertigo associated with
ipsilateral cochlear symptoms, such as fluctuating sensorineural hearing loss (SNHL), tinnitus or
aural pressure (1, 2).
Vestibular Migraine (VM) is defined by the occurrence of episodic vestibular symptoms
and a history of migraine, with a temporal association in at least 50% of the attacks (3). VM
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has an estimated population prevalence of about 1%, however
with only medical history and symptomology it may be
indistinguishable from MD at times (4–6).
It has been described that 8.4% of MD patients have headache
compatible with migraine, during vertigo attacks (7). The major
difference in the diagnosis criteria for these diseases are the
auditory symptoms, which are necessary for the diagnosis of
definite MD, however it has been reported that VM patients
may have tinnitus during vertigo attacks, and also that 25% of
migraine patients suffer from hearing loss (7, 8).
VM patients have a favorable response to anti-migraine drugs,
which supports an underlying migraine mechanism. However,
this evidence is insufficient as it is based on uncontrolled clinical
case series, thus the apparent efficacy may be due to confounding
factors, such as placebo response, spontaneous improvement and
multiple drug effect (3). Moreover, a high prevalence of migraine
in patients with MD has been previously described, suggesting a
pathophysiological link between these diseases (8, 9).
Recently, the Meniere’s disease Consortium identified five
clinical subgroups in patients with unilateral and bilateral MD:
Group 1 was defined by SNHL starting first in one ear and
involving the second ear in the next months or years; Group 2
characterized by simultaneous hearing loss in both ears since the
onset of the disease; Group 3 clustered familial MD; Group 4
associated with migraine in all cases and Group 5 was found in
patients with an autoimmune disease in addition to MD (10, 11).
Additionally, Frejo et al have observed two subgroups of MD
patients, according to their IL-1β profile, patients with high levels
of IL-1β (MDH) or patients with low levels of IL-1β (MDL),
which may have different immune responses or functional states
of the immune system (12).
Considering that the cytokine profile may allow to subgroup
MD patients and the clinical similarity of MD and VM, we
propose to investigate if the pro-inflammatory signature of these
diseases may allow to distinguish these patients.
MATERIALS AND METHODS
Human Subjects
This study included a total of 129 patients with definite MD,
82 patients with VM, and 66 healthy controls. Patients were
diagnosed according to the diagnostic criteria of the Barany
Society for MD (1) and VM (3). The experimental protocols
of this study were approved by the Institutional Review Board
in all participating hospitals and every patient signed a written
informed consent. The study was carried out according to the
principles of the Declaration of Helsinki revised in 2013 for
investigation with humans.
PBMC Isolation and Incubation
Peripheral blood was diluted 1:1 with 1 × PBS and disposed
carefully onto the corresponding 25:15 volume of Lymphosep,
Lymphocyte Separation Media (Biowest, Nuaillé, France).
Samples were centrifuged for 20min at 2,000 rpm to separate
blood content. PBMC were collected and washed with 1 × PBS
and cultured in RPMI 1640 supplemented with 10% (v/v) fetal
bovine serum (Biowest, Nuaillé, France) and plated at 1.25× 106
cells/mL in 6-well plates. PBMC were incubated during 16 h at
37◦C in 7% CO2. After the incubation, PBMC were centrifuged,
RNA was harvested, and supernatants were collected and stored
at−80◦C.
RNA Extraction and Expression Array
RNA was isolated using the High Pure RNA Isolation
Kit (Hoffmann-La Roche, Basel, Switzerland) following the
manufacturer’s protocol. RNA concentration was measured
on Nanodrop (NanoDrop Technologies Inc.,Wilmington, DE,
USA). RNA quality was checked using Agilent 2100 Bioanalyzer
(Agilent Technologies, Waldbronn, Germany).
Expression levels were measured using the HumanHT-12 v4
Expression BeadChip (Illumina Inc., San Diego, CA, USA) with
500 ng of total RNA and processed with the high-resolution
scanner iScan (Illumina Inc., San Diego, CA, USA).
The number of biological replicates for each condition was: 5
healthy controls, 4 MD patients with low cytokine basal levels, 3
MD patients with high cytokine basal levels and 6 VM patients.
Expression data analysis, normalization, differential
expression analysis and Principal Component Analysis (PCA)
was carried out as previously described by Frejo et al. (12). For
pairwise comparisons fold-change>2 and adjusted p-value 0.05
cut-offs were used.
Core analysis was performed using Ingenuity Pathways
Analysis (IPA R©, Qiagen, Venlo, Netherlands, http://www.
ingenuity.com/products/ipa) software, using the differentially
expressed genes (DEG) with an adjusted p-value cut-off of 0.02.
Cytokine Measurement
Supernatants were collected and stored at −80◦C until enough
samples were acquired. Frozen samples were thawed immediately
prior to analysis and none of the samples underwent more
than two freeze-thaw cycles prior to analysis. Fourteen cytokines
(IFNα-2, IFN-γ, IL-10, IL-1α, IL-1β, IL-1rα, IL-4, IL-6, IL-
12p40, IL-12p70, IL-13, IL-17, IL-28A, and TNFα), and
11 chemokines (IL-8, CXCL10, CCL2, CCL3, CCL4, CCL5,
CD40LG, CXCL1, CCL22, CXCL5, and CCL8) were measured
using the commercially available Multiplex Bead-Based Kits
(EMD Millipore, Billerica, MA, USA). The measurements were
done in accordance with the kit-specific protocols provided
by Millipore, using a Luminex 200 (Luminex Corp., Austin,
TX, USA) and read with Luminex x PONENT 3.1 software
(Luminex Corp.). The minimum detection limit for the assays
can be found in Table 1. Samples with readings below or above
these levels were assigned values of 0 pg/mL for the minimum
value or 10,000 pg/mL for the maximum value. Two quality
controls for each cytokine were run in duplicate. As the levels
of IL-12p40, IL-12p70, IL-13, IL-17, and IL-28A were low or
undetectable among all groups, they were excluded from the
statistical analysis.
Statistical Analysis
A descriptive analysis was conducted using SPSS software v.22
(SPSS Inc., Chicago, IL, USA) for the clinical data and displayed
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TABLE 1 | Assay sensitivity determined as Minimum Detection Concentration plus




























as mean ± standard error for the mean (SEM). Quantitative
variables were compared using Mann-Whitney U test, Student’s
unpaired T-test and Krustal-Wallis H test. Qualitative variables
were compared using Pearson Chi-square Test and Krustal-
Wallis H test. The level of significance considered was p-
value < 0.05.
Representative heatmaps of the cytokine levels were done
using the gplots package for R.
Logistic Regression
We identified cytokines with differential production between
MD and VM using Mann-Whitney test. Next, we performed
logistic regressions, removing step-by-step the variables which
had higher p-values, until we obtained a model for which
all cytokines were significant. The coefficient of determination
R2, which summarizes the proportion of variance in the
dependent variable associated with the predictor variables,
was estimated by using Nagelkerke’s R2. A receiver operating
characteristic (ROC) curve was generated to determine the
ability to predict VM based on a model composed of cytokine
production. Area under the curves (AUC) was calculated for the
ROC curves.
RESULTS
VM Has an Earlier Onset Than MD
Table 2 compares the clinical features of 129 MD patients (26
MDH and 103 MDL) and 82 VM patients. Patients with VM
were younger (p = 1.20 × 10−5) and had an earlier onset of
the disease (p = 4.41 × 10−4) than MD patients. As expected,
MD patients had worse hearing (p = 5.32 × 10−22), higher
number of vertigo attacks (p = 2.87 × 10−3) and were more
functionally affected by the disease (p = 1.44 × 10−11), when
compared to VM patients. A significant difference was found
in the prevalence autoimmune disease between VM and MD,
namely MDL had the highest history of autoimmune disease
(p = 9.77 × 10−3). On the other hand, VM patients suffered
more from headaches (p = 4.43 × 10−16), and more specifically
migraine episodes (p= 1.89× 10−26) than MD patients. We also
observed a higher number of drop attacks in patients with MDH
(p-value= 2.24× 10−14).
Gene Expression Profile on PBMCs can
Differentiate MD, VM, and Healthy Controls
We compared gene expression profiles of PBMCs from 6 VM
patients, 7 MD patients [4 with low basal levels of IL-1β and 3
with high basal levels of IL-1β (12)] and 5 healthy controls.
Using 1,894 genes, with 2 fold-change (FC) and an adjusted
p-value = 0.05, the samples were clustered into 4 distinct groups
by Principal Component Analysis (PCA), which corresponded to
our 3 patient groups and healthy controls, as seen in Figure 1.
Additionally, the hierarchical clustering of patients and controls
according to the gene expression in PBMC, shows that MDL are
more similar to healthy controls than to MDH.
Pairwise comparisons between groups were carried out due
to inter-individual variability. We firstly compared the gene
expression profile in PBMC from patients with VM and
healthy controls and found 832 DEG (p-value < 0.02 and
FC>2; Supplementary Table 1), being the most significant gene
CACNA2D2 (-5.3 FC and adjusted p-value = 5.89 × 10−6). The
core analysis with IPA software gave us a list of 25 networks.
The top ranked network had a score of 37 and 30 focus
molecules (Figure 2).
Additionally, we compared the gene expression profile in
PBMC from patients with VM to MDH and MDL separately
(Supplementary Tables 2, 3). We observed that 22 genes were
differentially expressed in both comparisons, from which
we retrieved a network with 10 focus molecules (score 23,
Figure 3A). Of note, 286 genes were uniquely expressed when
comparing PBMC from patients with VM to MDH, resulting in
a top network with 22 focus molecules (score 32, Figure 3B).
Moreover, 136 genes were uniquely expressed when comparing
PBMC from patients with VM toMDL, resulting in a top network
with 22 focus molecules (score 41, Figure 3C).
VM Patients Have Similar Cytokine Levels
to MD Patients With Low Basal Levels of
IL-1β
The expression array revealed significant differences in various
cytokines and chemokines, therefore we decided to measure
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TABLE 2 | Clinical and demographic variables assessed in patients with Meniere Disease with high levels of IL-1β (MDH), Meniere Disease with low levels of IL-1β (MDL),
and Vestibular Migraine (VM).
Variable MDH (N = 26) MDL (N = 103) VM (N = 82) p-value
Age (mean ± SD) 60.6 ± 11.2 59.3 ± 13.7 48.6 ± 16.0 1.20 × 10−5
Years of Evolution (mean ± SD) 12.0 ± 11.0 10.1 ± 8.5 10.9 ± 10.2 0.875
Age of onset (mean ± SD) 44.4 ± 10.5 47.3 ± 15.7 37.1 ± 17.2 4.41 × 10−4
Sex (% female) 50 63.6 65.1 0.366
Laterality (% unilateral) 50.8 63 NA 0.264
Affected ear (% right ear) 26.9 27.6 NA 0.321
Hearing loss (% synchronic) 30.4 18 NA 0.342
Time until evolving to bilateral (months) 125.0 ± 118.6 55.8 ± 59.9 NA 0.106
MD type 0.736
1 69.6 64.4 NA
2 0 4.4 NA
3 8.7 7.8 NA
4 13 10 NA
5 8.7 13.3 NA
Hearing stage (%) 5.32 × 10−22
1 15.4 6.3 92.7
2 26.9 29.2 7.3
3 30.8 47.9 0
4 26.9 15.6 0
5 0 1 0
Ear Family History (%) 12 29.4 34.9 0.130
Familial Meniere disease (%) 8.3 10.1 5,4 0.466
Headache (%) 38.5 37.6 98.6 4.429 × 10–16
Type of headache 2.117 × 10−7
Migraine 50 51.4 94.6
Tensional 50 48.6 5.4
Migraine (%) 20 20.5 100 1.887 × 10−26
Type of Migraine 0.569
Migraine with Aura 60 42.9 58.3
Migraine without Aura 40 57.1 41.7
History of autoimmune disease (%) 7.7 17.3 1.7 9.77 × 10−3
Tumarkin crises (drop attacks) 1.9 ± 0.3 1.6 ± 0.7 NA 2.241 × 10−14
Number of crisis in last 6 months 2.3 ± 3.0 2.0 ± 3.0 1.4 ± 2.1 2.87 × 10−3
AAO-HNS Functional level (1–6) 0.241
1 8 17.9 70.9 1.44 × 10−11
2 44 29.8 20
3 16 27.4 9.1
4 20 16.7 0
5 12 6 0
6 0 2.4 0
Significant differences for p-value < 0.05 are highlighted in bold.
the levels of IFNα-2, IFN-γ, IL-10, IL-1α, IL-4, IL-8, CXCL10,
CCL2, CCL3, CCL4, CCL5, CD40LG, CXCL1, CCL22, CXCL5,
and CCL8 in a smaller cohort of patients, which included 24
MDH patients, 24 MDL patients, 20 VM patients and 10 healthy
controls. Levels of IL-1β, IL-1RA, IL-6, and TNFαwere measured
in all cases and controls, in line with previous work carried out by
our group (12).
The cytokines can be separated into 3 groups according to
their levels: (a) high cytokine production in all groups, (b)
cytokines which are higher in MDH than in the other groups
and (c) cytokines that are higher in patients than in controls, as
observed in Figure 4.
Also, we can observe that the cytokine levels of VM patients
are very similar to MDL patients and that controls always have
lower cytokine levels than the patients.
CCL4 Levels May Allow to Distinguish
Between MD, VM and Healthy Controls
MDL had the lowest number of cytokines that were statistically
different from healthy controls, as no differences were found
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FIGURE 1 | Gene expression in PBMC. (A) Dendrogram showing hierarchical clustering of patients and controls according to the gene expression in PBMC.
(B) Three-dimensional loading plot showing principal component analysis (PCA) using all datasets. (C) Matrix of up- and down- regulated genes for selected pairwise
comparisons. Values indicate the number of up- or down- regulated genes with a fold-change (FC) >2 and P-value < 0.02. In green are the up-regulated genes
(positive FC) and in orange are the down-regulated genes (negative FC).
in the levels of IL-10, IL-1β, IL-6, CCL5, CXCL1, IFNA2, and
CXCL5 (all, p > 0.1) (Supplementary Table 4). On the other
hand MDH had statistically different levels of all cytokines
comparing to healthy controls (p= 1.64×10−12-4.61×10−2].
Overall, MDH patients have higher levels of all cytokines,
except for CCL22 (p= [2.12× 10−4−3.01× 10−2]) and CXCL10
(p= [2.18× 10−4-2.10× 10−2]), for which VM patients hold the
highest levels.
We observed that CCL4 allows to distinguish between all
groups of patients and between patients and controls (by pairwise
comparison p = [6.30×10−5-1.04×10−2]). Moreover, CXCL10
allows to distinguishmost groups p= [2.18×10−4-3.84× 10−2]),
however it does not discriminate MDH fromMDL (p= 0.354).
Despite the high similarity of cytokine levels of VM patients
and MDL patients, the levels of IL-10 (p-value = 9.84×10−3),
CXCL1 (p-value= 1.42× 10−3), and IL-8 (p-value= 9.79×10−3)
are significantly higher in PBMC from VM patients than in
MDL patients.
IL-1β, CCL3, CCL22, and CXCL1 Levels
May Allow to Distinguish Between MD and
VM Patients
In order to discriminate VM patients from MD patients, we
performed logistic regressions with the differentially released
cytokines between MD and VM, for which we obtained a
final regression model that included IL-1β, CCL3, CCL22, and
CXCL1 levels as independent variables (Table 3). The ability
of the model to predict patients with VM was assessed by
plotting a ROC curve using the variables from the logistic
regression, which has a 93.8% sensitivity, 95.8% specificity, 97.8%
positive predictive value and 11.8% negative predictive value
(Figure 5). Other regressionmodels using three, two or one of the
cytokines were also evaluated, but all showed a lower diagnostic
accuracy (Table 4).
DISCUSSION
Our study shows that a small panel of cytokines and chemokines
could be used for the differential diagnosis of VM andMD. Given
that both conditions have a different therapeutic approach, our
findings may contribute to improve the clinical management of
VM and MD.
We observed that VM patients suffer more from migraine
(p = 1.87 × 10−26) and have approximately a decade earlier
onset than MD patients, (p = 1.20 × 10−5) and MD patients
have more severe hearing loss (p = 5.32 × 10−22). Nevertheless,
there is a symptom overlap which could be especially difficult
to discriminate in earlier stages of the disease. Interestingly,
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FIGURE 2 | Top Network from VM patients PBMCs at basal levels. Network retrieved after comparing by pairwise analysis gene expression data from VM patients to
healthy controls. Genes in red were up-regulated, while genes in green were down-regulated.
MD type 4 patients, which are sporadic MD patients that suffer
from migraine have been described to have a significantly earlier
onset than the remaining MD patients (10, 11). These MD
patients with comorbid migraine show migraine attacks that
most of times are not associated with the episodic vertigo,
but the temporal relationship between vertigo and migraine
in MD needs to be investigated in a prospective longitudinal
study. Specifically, bilateral MD type 4 (10) has the same
mean age of onset (37 years old) as VM patients from our
study, which further supports the necessity of a method to
distinguish VM and MD patients that is not fully dependent of
clinical information.
Our gene expression and cytokine results indicate that
MDH and MDL are more similar between them than to
VM. These results further support the hypothesis that MD is
not a single disease or that it has various endophenotypes.
Different MD subgroups have been already identified according
to clinical manifestations and phenotype (10–12) and according
to endolymphatic sac (ES) imaging (13).
Despite VM and MDL molecular similarity, these diseases
seem to have distinct disease mechanisms, as there are 158
differentially expressed genes. When we compared the uniquely
expressed genes between VM and MDL, we observe that the
genes involved in the retrieved network are related to immune
response, which seems to be upregulated in VM.
The presence of immunological activity in the inner ear
has been previously described, both in animal models and
humans. Immune responsiveness in the inner ear was firstly
associated to the ES (14–16), however the presence of immune
capacity in the cochlea has since been determined (17),
namely due to the recent demonstration of IBA1 cells in the
human ES and cochlea that express Major Histocompatibility
Complex Type II (MHCII) (18). Nordström et al. (18)
identified that the macrophage population of the stria vascularis,
spiral ligament and spiral ganglion expressed MHCII, which
is essential to initiate antigen-specific immune responses.
Moreover, they propose that there might be an uptake and
processing of antigens from the ES lumen, due to the co-
expression of IBA1 and MHCII in epithelial cells and to
trans-epithelial migration.
Here, we show that IL- 1β, CCL3, CCL22, and CXCL1
quantification could allow the differential diagnosis of VM
and MD.
CXCL1, also known as GRO-α (Growth-related Oncogen-
alpha) has an essential role in the recruitment and activation
of neutrophils, mediating its function through CXCR2 signaling
on neutrophils and by binding to glycosaminoglycans (GAG)
on endothelial and epithelial cells and the extracellular
matrix (19). CXCL1 is usually lower in patients with MD
compared to VM.
CCL3 or MIP1- α (Macrophage Inflammatory Protein 1-
alpha) is a macrophage secreted chemokine with inflammatory
and chemokinetic properties, with CCR1, CCR4 and CCR5
binding. Recently, ES fibroblast cell lines, derived from MD
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FIGURE 3 | Differentially expressed genes comparing VM to MDH and MDL. (A) Network obtained after taking common genes from pairwise comparison between
MDH and VM and MDL and VM. (B) Network retrieved in MDH patients unique differentially expressed genes (DEG), after pairwise comparison to VM. (C) Network
retrieved in MDL patients unique DEG, after pairwise comparison to VM. Genes in red were up-regulated, while genes in green were down- regulated.
patients have been established by Yamada et al. (20) and
they observed that these cells produce CCL3 and that its
production can be increased after Toll-like receptor (TLR) 3
and TLR4 stimulation. Moreover, they observed production
of other cytokines, such as IL- 1β, CXCL10, thymic stromal
lymphopoietin (TSLP), B lymphocyte stimulator (BLyS), IL-6
and IL-8. The levels of CCL3 are lower in patients with VM
compared to MD, but higher than in healthy controls. Elevated
levels of CCL3 have been reported in patients with migraine (21),
which could support the hypothesis that VM shares migraine
mechanisms (3).
CCL22 or MDC (Macrophage-derived chemokine) is a
chemoattractant for monocytes, dendritic cells and natural killer
cells and it binds to CCR4. IL-1β is a potent inflammatory
mediator and is associated with various cellular mechanisms,
such as cell activation, proliferation, and apoptosis (22). Yoshida
et al cultured murine spiral ligament fibrocytes and verified
that IL- 1β and TNFα stimulation resulted in production
of various cytokines and chemokines, namely IL-6 and
CCL2 (23).
The expression of CXCL1, CCL3, CCL22, and IL- 1β has been
observed in mouse cochlear tissue (24), and CXCL1, CCL3, and
IL-1β were also found in cells from the ES (25). Interestingly
CXCL1 is the only chemokine which expression was also found
in mouse vestibular cells (26) and of the four cytokines had the
highest expression in all tissues.
Considering that we observed a cytokine increase in PBMCs
extracted from peripheral blood, this could indicate that
patients with MD and VM have a systemic proinflammatory
response, which could explain some patients response to
anti-inflammatory drugs (2, 27). On the other hand, this
increased production of cytokines could also affect or represent
activity that is occurring in the inner ear, thus the observed
secretion of cytokines/chemokines may present a prolonged
inflammatory response, leading to inner ear damage, through
epithelial disruption.
Some studies have quantified cytokine levels in serum from
migraine patients during the attack and non-attack periods.
Fidan et al. (28) observed that IL-6 is higher in both periods
when compared to healthy controls; CCL5, IL-10 and nitric
oxide were only elevated during attack periods and TNFα, IL-1,
IL-2, IFNγ, CCL2, CCL3, and CCL4 had no differences. On the
other hand, Yucel et al. (29) saw an increase of CNDN5, ESM-
1, IL-6, IL-1β, and TNFα during attacks. Additionally, Munno
et al. (30) described an increase in TNFα, IL-4, and IL-5 in
migraine patients, but no differences in IL-10 and IFNγ. In
our work, we observed that VM patients had elevated levels
of CCL5, IL-10, IL-1β, IFNγ, CCL2, CCL3, CCL4, and IL-4
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FIGURE 4 | Heatmap of cytokine/chemokine concentrations [log10(concentration (pg/mL) +1)] with dendrogram showing hierarchical clustering of patients and
controls.
TABLE 3 | Logistic regression model to predict VM including IL-1β, CCL3,
CXCL1, and CCL22 (Negelkerke’s R2 = 0.909).
B SE Wald Exp(B) 95% CI for EXP(B) p-value
IL-1β −1.99 0.94 4.50 0.14 0.02–0.86 0.03
CCL3 −1.07 0.45 5.68 0.34 0.14–0.83 0.02
CXCL1 0.02 0.01 5.22 1.02 1.00–1.04 0.02
CCL22 0.05 0.02 4.38 1.05 1.00–1.10 0.04
The total accuracy of the model was 95.2%.
(Supplementary Table 4) when compared to healthy controls,
but no statistical differences in IL-6 and TNFα levels were found.
Therefore, a comparison between VM patients and migraine
patients, namely IL- 1β, CCL3, CCL22, and CXCL1 levels, could
be beneficial to understand if there is a shared cytokine profile
between migraine and VM or if this cytokine signature is specific
to VM.
Autoinflammatory diseases are caused by a hyperactive
inflammatory response, that leads to an immune deregulation,
driven by IL-1, type I interferon, and NFκB (31). These
diseases usually manifest themselves in the perinatal period,
however milder and later-onset forms are being diagnosed in the
adulthood (32). Some of these disorders have manifestations that
mimic allergic and immunodeficiency disorders (31). Moreover,
many of these diseases have sensorineural hearing loss as a
symptom (31, 32). Autoimmune inner ear disease (AIED) is
characterized by recurrent episodes of bilateral SNHL occurring
over a period of several weeks or months (33). AIED has
an overlapping audiovestibular phenotype with MD. Patients
with AIED present elevated levels of proinflammatory cytokines,
such as IL-1β and TNFα which resembles an autoinflammatory
phenotype (33, 34). Recent efforts have been made to expand
the immunological disease continuum to include monogenic and
complex immune disorders that present both autoinflammatory
or autoimmune manifestations, where diseases such as AIED
would fall (33). Thus, considering the overall elevated levels
of proinflammatory cytokines in patients with MDH and
the similarity to AIED, we propose that MDH should be
considered an autoinflammatory condition, yet longitudinal
studies would be necessary to determine if these patients present
continuously elevated proinflammatory cytokine levels or if it is
a fluctuating condition.
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FIGURE 5 | Predictive biomarkers for Vestibular Migraine. Scatter dot plots showing the measured levels for IL-1β (A), CCL22 (B), CCL3 (C), and CXCL1 (D) in
patients with VM and MD. (E) Receiver operating characteristic (ROC) curves to predict VM with IL-1β, CXCL1, CCL3, and CCL22. AUC (area under the curve) =
0.995.
TABLE 4 | Different multivariant or univariant models using IL-1β, CXCL1, CCL3,
CCL22 as predictive variables.
Variables AUC % loss
IL-1β, CXCL1, CCL22, CCL3 0.993
IL-1β, CXCL1, CCL22 0.962 3.1%
CXCL1, CCL22, CCL3 0.948 4.7%
CXCL1, CCL22 0.794 21.0%
IL-1β, CCL22, CCL3 0.945 6.0%
IL-1β, CCL22 0.921 7.6%





AUC–area under the curve.
In this study we were able to find a method that could allow a
more accurate differential diagnosis between VM and MD. Since
the cohort of patients for which we could measure all cytokines
was limited (VM = 16 and MD = 48), these results should
be replicated in a larger cohort of patients with VM, MD, and
Migraine, also considering clinical variables to better characterize
MD endophenotypes.
CONCLUSION
Patients with MD or VM have a different pro-inflammatory
signature. A cytokine panel including IL- 1β, CCL3, CCL22, and
CXCL1 could be used as biological markers for the differential
diagnosis of VM and MD.
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